News|Podcasts|February 19, 2026
From Launch to Loss of Exclusivity: Reducing Access and Affordability Barriers Across the Brand Lifecycle
Author(s)CoverMyMeds
Access and affordability challenges continue to evolve across every phase of the biopharma brand lifecycle. Megan Wetzel, Vice President of Product, Access & Affordability at CoverMyMeds, shares actionable, lifecycle-specific approaches to removing barriers, easing provider burden, and supporting patient adherence. These strategies offer guidance for strengthening brand performance from launch through maturity while improving patient outcomes.
What you’ll learn:
- Discover how access barriers evolve across the biopharma brand lifecycle, from launch to loss of exclusivity, and how to address them proactively.
- Learn how data-driven insights and affordability solutions can help biopharma support providers and pharmacists at every stage.
- Understand the strategic role of lifecycle planning in improving medication access, reducing industry fragmentation and enhancing patient outcomes.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Related Content
The Transformative Role of Medical Information in Customer Engagement
ByIndegene
Published: | Updated:
Unlocking value and cost savings in patient services with technology and talent
Published: | Updated:
Trending on PharmExec
1
FDA Removes Two Study Requirement for New Drug Approval Process: Report
2
From Sun Belt Boom to Biotech Hub: Why Southern Florida’s Moment has Arrived
3
Pharmaceutical Executive Daily: FDA Initiates Review of Moderna’s Seasonal Influenza Vaccine
4
Eli Lilly Announces Positive Results for Treating Crohn’s Disease with Omvoh
5